2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12A.04 Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib

P1.12A.04 Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib

Back to course

Pdf Summary

The retrospective study investigates survival disparities in ethnic-minority patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with Osimertinib at the Montefiore Einstein Comprehensive Cancer Center (MECCC). The cohort included 168 patients diagnosed with lung cancer, out of which 32.7% were Hispanic, 28.6% Non-Hispanic White, 26.2% Non-Hispanic Black, and 12.5% Asian. The median age was 69, with a follow-up period averaging 16.3 months. The study found significant disparities in progression-free survival (PFS) and overall survival (OS) among ethnic groups, with Non-Hispanic Blacks showing inferior survival outcomes compared to Non-Hispanic Whites, despite similar adherence levels.<br /><br />The study analyzed clinical and socioeconomic factors influencing survival outcomes, finding notable differences in smoking status, body mass index (BMI), type of insurance, income, and overall survival rates. Specifically, Medicaid recipients had the lowest OS, whereas Medicare recipients exhibited higher survival rates. Income below $50,000 was associated with a higher risk of death compared to incomes above $50,000. The study highlights the necessity for further prospective research to assess pharmacogenetics and dosage optimization, particularly in ethnic minorities who may metabolize Osimertinib less effectively due to genetic variations.<br /><br />Overall, the findings stress the importance of considering socioeconomic and pharmacogenetic factors when treating ethnic minorities with EGFR-mutated NSCLC to address the observed survival disparities. The study received support from MECCC and AstraZeneca, and it aims to provide a basis for future research focusing on bridging the knowledge gap regarding treatment and clinical outcomes in diverse populations.

Asset Subtitle

Matthew Lee

Meta Tag

Speaker Matthew Lee

Topic Metastatic NSCLC – Targeted Therapy

Keywords

survival disparities

ethnic-minority patients

EGFR-mutated NSCLC

Osimertinib

Montefiore Einstein Comprehensive Cancer Center

progression-free survival

overall survival

socioeconomic factors

pharmacogenetics

treatment outcomes